Detalhe da pesquisa
1.
Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study.
Br J Dermatol
; 189(1): 33-41, 2023 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36972293
2.
Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study.
Br J Dermatol
; 187(6): 878-887, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35986699
3.
A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis.
Arthritis Res Ther
; 26(1): 117, 2024 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38845046
4.
Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors.
Bioorg Med Chem Lett
; 23(10): 3059-63, 2013 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23566514
5.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and Participants with Atopic Dermatitis: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study.
J Clin Pharmacol
; 2023 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37772436
6.
Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial.
Arthritis Rheumatol
; 75(8): 1370-1380, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37194394
7.
Increased serum enzyme levels associated with kupffer cell reduction with no signs of hepatic or skeletal muscle injury.
Am J Pathol
; 179(1): 240-7, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21703406
8.
A Phase 1 Study to Assess Mass Balance and Absolute Bioavailability of Zimlovisertib in Healthy Male Participants Using a 14 C-Microtracer Approach.
Clin Pharmacol Drug Dev
; 11(7): 815-825, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35506501
9.
Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With Abrocitinib.
Dermatitis
; 32(1S): S53-S61, 2021 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33795561
10.
Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate.
Arthritis Rheumatol
; 72(10): 1621-1631, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32419304
11.
Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
JAMA Dermatol
; 155(12): 1371-1379, 2019 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31577341
12.
Discovering in vivo cytokine-eQTL interactions from a lupus clinical trial.
Genome Biol
; 19(1): 168, 2018 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-30340504
13.
Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.
Clin Cancer Res
; 11(5): 2063-73, 2005 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15756033
14.
Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
Cancer Res
; 63(21): 7301-9, 2003 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-14612527
15.
Microarray analysis uncovers retinoid targets in human bronchial epithelial cells.
Oncogene
; 22(31): 4924-32, 2003 Jul 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-12894236
16.
Evidence for the epidermal growth factor receptor as a target for lung cancer prevention.
Clin Cancer Res
; 8(1): 54-60, 2002 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-11801540
17.
Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study.
J Clin Pharmacol
; 54(1): 14-22, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23913720
18.
PF-03475952: a potent and neutralizing fully human anti-CD44 antibody for therapeutic applications in inflammatory diseases.
Adv Ther
; 27(3): 168-80, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-20429046
19.
Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity.
Bioorg Med Chem Lett
; 14(1): 21-4, 2004 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-14684289